Furthermore data revealed a relationship between treatment of CD133+ cancer cells with anti-CD3/anti-CD133 bispecific antibody-Cytokine Induced Killer (CIK) cells and S100P downregulation in the targeted tumor cells. This evidence concerns the gene PROM1 and neoplasm.